GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » Beneish M-Score

TriSalus Life Sciences (TriSalus Life Sciences) Beneish M-Score : -8.01 (As of May. 24, 2024)


View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -8.01 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for TriSalus Life Sciences's Beneish M-Score or its related term are showing as below:

TLSI' s Beneish M-Score Range Over the Past 10 Years
Min: -8.01   Med: -8.01   Max: -8.01
Current: -8.01

During the past 3 years, the highest Beneish M-Score of TriSalus Life Sciences was -8.01. The lowest was -8.01. And the median was -8.01.


TriSalus Life Sciences Beneish M-Score Historical Data

The historical data trend for TriSalus Life Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences Beneish M-Score Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Beneish M-Score
- - -

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only - - - - -8.01

Competitive Comparison of TriSalus Life Sciences's Beneish M-Score

For the Medical Devices subindustry, TriSalus Life Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TriSalus Life Sciences's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where TriSalus Life Sciences's Beneish M-Score falls into.



TriSalus Life Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of TriSalus Life Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.528+0.528 * 0.9172+0.404 * 1.4043+0.892 * 1.7582+0.115 * 0.8081
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9722+4.679 * -1.470848-0.327 * 0.7308
=-8.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $4.28 Mil.
Revenue was 6.457 + 5.721 + 5.193 + 4.612 = $21.98 Mil.
Gross Profit was 5.486 + 5.139 + 4.604 + 3.84 = $19.07 Mil.
Total Current Assets was $13.19 Mil.
Total Assets was $17.89 Mil.
Property, Plant and Equipment(Net PPE) was $3.16 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.54 Mil.
Selling, General, & Admin. Expense(SGA) was $45.06 Mil.
Total Current Liabilities was $14.39 Mil.
Long-Term Debt & Capital Lease Obligation was $1.22 Mil.
Net Income was -13.219 + -35.509 + -1.286 + -13.974 = $-63.99 Mil.
Non Operating Income was -1.62 + -21.631 + 17.079 + -2.559 = $-8.73 Mil.
Cash Flow from Operations was -10.867 + -8.849 + 0 + -9.229 = $-28.95 Mil.
Total Receivables was $1.59 Mil.
Revenue was 2.984 + 3.226 + 3.923 + 2.37 = $12.50 Mil.
Gross Profit was 2.322 + 2.41 + 3.222 + 1.994 = $9.95 Mil.
Total Current Assets was $15.19 Mil.
Total Assets was $19.84 Mil.
Property, Plant and Equipment(Net PPE) was $3.43 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.46 Mil.
Selling, General, & Admin. Expense(SGA) was $26.36 Mil.
Total Current Liabilities was $22.19 Mil.
Long-Term Debt & Capital Lease Obligation was $1.50 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.277 / 21.983) / (1.592 / 12.503)
=0.194559 / 0.127329
=1.528

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(9.948 / 12.503) / (19.069 / 21.983)
=0.795649 / 0.867443
=0.9172

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (13.191 + 3.161) / 17.889) / (1 - (15.194 + 3.434) / 19.842)
=0.085919 / 0.061183
=1.4043

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=21.983 / 12.503
=1.7582

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.459 / (0.459 + 3.434)) / (0.54 / (0.54 + 3.161))
=0.117904 / 0.145907
=0.8081

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(45.058 / 21.983) / (26.359 / 12.503)
=2.049675 / 2.108214
=0.9722

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.218 + 14.394) / 17.889) / ((1.501 + 22.194) / 19.842)
=0.872715 / 1.194184
=0.7308

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-63.988 - -8.731 - -28.945) / 17.889
=-1.470848

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

TriSalus Life Sciences has a M-score of -8.01 suggests that the company is unlikely to be a manipulator.


TriSalus Life Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


TriSalus Life Sciences (TriSalus Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
6272 W. 91st Avenue, Westminster, CO, USA, 80031
TriSalus Life Sciences Inc is an oncology company integrating standard-of-care treatments and its investigational immunotherapeutic, SD-101, with disruptive Pressure Enabled Drug Delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. TriSalus is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company.
Executives
Jodi Devlin officer: President, Therapeutics C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih officer: President, Device Technology C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Bryan F. Cox officer: Chief Scientific & Manufact. C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks director C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
George Kelly Martin director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jennifer Stevens officer: Chief Regulatory Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak officer: Sr.VP, Corp. Dev. & Strategy C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mary T Szela director, officer: CEO and President 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Anil K. Singhal director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Sean Murphy director, officer: Chief Financial Officer C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz officer: Chief Medical Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mats Wahlstrom director, 10 percent owner 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Equity Ab Frankenius 10 percent owner BOX 984, BORAS V7 SE-501 10